Literature DB >> 17476572

Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease.

Masaru Miyanaga1, Tatushi Kawaguchi, Kentaro Shimizu, Kazunori Miyata, Manabu Mochizuki.   

Abstract

PURPOSE: To evaluate the importance of early cerebrospinal fluid (CSF)-guided diagnosis and early high-dose corticosteroid therapy on the complications and visual prognosis of Vogt-Koyanagi-Harada (VKH) disease. PATIENTS AND METHODS: Charts from patients with VKH disease who had been seen at Tokyo Medical and Dental University Hospital and Miyata Eye Hospital between 1994 and 2002 were retrospectively reviewed. The patients were classified into two groups. The first group (group A) consisted of patients who had received a full work-up including CSF examination and corticosteroid pulse therapy at the acute ophthalmic stage of disease. The second group (group B) consisted of patients who were referred to us by local ophthalmologists long after the disease onset, had not had a CSF examination and had been treated with low-dose systemic corticosteroids or topical corticosteroid therapy. The ocular complications, systemic complications and visual prognosis were compared between the two groups.
RESULTS: Twenty-two patients were included in group A and ten patients in group B. The initial diagnosis at the acute ophthalmic stage had been VKH disease in all patients of group A, while, in group B, the diagnosis was idiopathic uveitis in six patients (60%) initially. Frequency of recurrent uveitis and integumentary symptoms were significantly lower in group A. Intensity of sunset glow fundus was significantly more severe in group B. All eyes in group A obtained a final visual acuity of 0.8 or better, whereas 11 eyes (55%) in group B were below this level.
CONCLUSIONS: The results indicate that early diagnosis, helped by CSF examination and early high-dose corticosteroid therapy, decreased the complication rate and improved the visual prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17476572     DOI: 10.1007/s10792-007-9076-3

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.029


  12 in total

1.  Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats.

Authors:  K Yamaki; I Kondo; H Nakamura; M Miyano; S Konno; S Sakuragi
Journal:  Exp Eye Res       Date:  2000-10       Impact factor: 3.467

2.  Vogt-Koyanagi-Harada syndrome.

Authors:  S Ohno; D H Char; S J Kimura; G R O'Connor
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

3.  Utility of existing Vogt-Koyanagi-Harada syndrome diagnostic criteria at initial evaluation of the individual patient: a retrospective analysis.

Authors:  R W Read; N A Rao
Journal:  Ocul Immunol Inflamm       Date:  2000-12       Impact factor: 3.070

4.  Analysis of 87 cases with Vogt-Koyanagi-Harada disease.

Authors:  S V Mondkar; J Biswas; S K Ganesh
Journal:  Jpn J Ophthalmol       Date:  2000 May-Jun       Impact factor: 2.447

5.  Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.

Authors:  R W Read; G N Holland; N A Rao; K F Tabbara; S Ohno; L Arellanes-Garcia; P Pivetti-Pezzi; H H Tessler; M Usui
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

6.  Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome.

Authors:  P E Rubsamen; J D Gass
Journal:  Arch Ophthalmol       Date:  1991-05

7.  [Vogt-Koyanagi-Harada syndrome: importance of rapid diagnosis and therapeutic intervention].

Authors:  N Bouchenaki; L Morisod; C P Herbort
Journal:  Klin Monbl Augenheilkd       Date:  2000-05       Impact factor: 0.700

8.  Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome.

Authors:  D J Forster; N A Rao; R A Hill; Q H Nguyen; G Baerveldt
Journal:  Ophthalmology       Date:  1993-05       Impact factor: 12.079

Review 9.  Vogt-Koyanagi-Harada syndrome.

Authors:  R S Moorthy; H Inomata; N A Rao
Journal:  Surv Ophthalmol       Date:  1995 Jan-Feb       Impact factor: 6.048

10.  Clinical studies of Vogt-Koyanagi-Harada's disease.

Authors:  S Ohno; R Minakawa; H Matsuda
Journal:  Jpn J Ophthalmol       Date:  1988       Impact factor: 2.447

View more
  8 in total

1.  Headache, red eyes, blurred vision and hearing loss. Diagnosis: Vogt-Koyanagi-Harada syndrome.

Authors:  Errol Wei'en Chan; Srinivasan Sanjay; Benjamin Chong Ming Chang
Journal:  CMAJ       Date:  2010-05-17       Impact factor: 8.262

2.  Headache as an initial manifestation of Vogt-Koyanagi-Harada disease.

Authors:  Abdulrahman Samir Khairallah
Journal:  Saudi J Ophthalmol       Date:  2013-10-14

3.  Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.

Authors:  Massimo Accorinti; Maria Carmela Saturno; Ludovico Iannetti; Priscilla Manni; Davide Mastromarino; Maria Pia Pirraglia
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 4.  Intraocular inflammation: its causes and investigations.

Authors:  Claire Hooper; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.919

Review 5.  Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

Authors:  Carl P Herbort; Ahmed M Abu El Asrar; Joyce H Yamamoto; Carlos E Pavésio; Vishali Gupta; Moncef Khairallah; Ilknur Tugal-Tutkun; Masoud Soheilian; Masuru Takeuchi; Marina Papadia
Journal:  Int Ophthalmol       Date:  2016-11-14       Impact factor: 2.031

6.  Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.

Authors:  Shizhao Yang; Tianyu Tao; Zhaohuai Li; Binyao Chen; Zhaohao Huang; Xiuxing Liu; He Li; Lihui Xie; Wen Feng; Wenru Su
Journal:  Ann Transl Med       Date:  2022-06

Review 7.  Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.

Authors:  Carl P Herbort; Ilknur Tugal-Tutkun; Ahmed Abu-El-Asrar; Amod Gupta; Masaru Takeuchi; Christine Fardeau; Alireza Hedayatfar; Cristhian Urzua; Ioannis Papasavvas
Journal:  Eye (Lond)       Date:  2021-06-18       Impact factor: 3.775

Review 8.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.